Boundless Bio, Inc. SEC filings BOLD

Boundless Bio, Inc. has 162 filings in SEC EDGAR's recent list, going back to Mar 12, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 28, 2026 (material agreement). The company's fiscal year ends on December 31.

Boundless Bio, Inc. SEC filings
Form Description Filed Period
424B3 Prospectus Nov 3, 2026 —
S-4/A Filing Nov 2, 2026 —
S-4 Registration for a merger or exchange Oct 8, 2026 —
S-3 Shelf registration Apr 1, 2025 —
S-8 Employee stock plan registration Mar 28, 2024 —
424B4 Prospectus Mar 28, 2024 —
S-1/A Amended registration statement Mar 21, 2024 —
S-1 Registration statement Mar 6, 2024 —

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BOLD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
La Jolla, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1782303

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.